treatment-cognitive

Interactive Simulator Legend: Convergent Evidence Across Three Analytical Scales

• Part 1. Nationwide Pharmacoepidemiological Scale: Observe the divergence in the graphical trajectories. While standard acetylcholinesterase inhibitors (AChEIs, e.g., donepezil) exhibit a distinctly increasing trend in crude death rates , drugs with H₂O₂-scavenging and myeloperoxidase (MPO)-inhibitory mechanisms (e.g., fluoxetine) demonstrate a consistently decreasing mortality trajectory over the 12-year observation period.

• Part 2. Natural Cohort Scale: Note the "bilateral symmetry" in the 15-year longitudinal data from the Sorokdo Island cohort. In an environment where confounding by dementia indication is structurally excluded , this visualizes a striking intersection: Alzheimer's disease incidence progressively declines in the dapsone (DDS)-exposed group, whereas it accelerates in the non-exposed group.

• Part 3. Clinical Validation Scale: The bar chart clearly illustrates that co-administration of cimetidine successfully overcomes the hematological barrier of methemoglobinemia, maintaining safe levels at a mean of 0.58%. Consequently, patients achieved a mean Mini-Mental State Examination (MMSE) improvement of +4.00 points within just 1 to 3 months. This overwhelmingly surpasses both the 12-week short-term peak efficacy (+1.10) and the 1-year long-term trajectory (-0.27) of standard donepezil therapy.